Adaptogenics Health Corp. (CSE: ADPT) announced on November 16, 2026, that it intends to conduct a non-brokered private placement of up to 2,500,000 units priced at $0.25 per unit, targeting gross proceeds of up to $625,000. The offering includes a warrant component exercisable at $0.75 per share over 24 months. The company says proceeds will fund e-commerce, nutritional products, peptide sourcing, and research and development initiatives, making this a financing round investors in the health and wellness space may be watching closely.
Key Points
- Adaptogenics Health Corp. (CSE: ADPT) announced a non-brokered private placement
- Up to 2,500,000 units offered at $0.25 per unit for gross proceeds of up to $625,000
- Each unit includes one common share and one-half of one warrant; full warrants exercisable at $0.75 for 24 months from issuance
- Investors should watch for CSE acceptance and closing tranche announcements, as the offering remains subject to regulatory approval
Unit Structure and Warrant Terms of the ADPT Offering
Each unit issued under the offering will consist of one common share and one-half of one common share purchase warrant. Every whole warrant will entitle its holder to acquire one additional common share of Adaptogenics at a price of C$0.75 for a period of 24 months from the date of issuance. All securities issued under the offering will be subject to a statutory hold period of four months and one day from issuance, in accordance with applicable Canadian securities laws. The offering is expected to close in one or more tranches, the company stated.
Planned Use of Proceeds Across Peptide and E-Commerce Operations
Adaptogenics disclosed that net proceeds from the offering are intended to advance its e-commerce platform, nutritional products business, peptide sourcing activities, and research and development initiatives. Funds will also support personnel costs, investor relations activities, and general working capital requirements. The company is focused on metabolic health, muscle preservation, mitochondrial biology, and inflammation, and is evaluating GLP-1 companion products intended to support nutritional health and muscle function alongside medically induced weight loss programmes.
Finder's Fees and Regulatory Conditions Attached to the Placement
The company may issue common shares to eligible finders equal to 7% of the units sold to subscribers they introduce, subject to applicable securities laws and Canadian Securities Exchange policies. The offering remains conditional on receipt of all necessary regulatory approvals, including formal acceptance by the Canadian Securities Exchange. The release notes that securities issued under this offering have not been registered under the United States Securities Act of 1933 and may not be offered or sold within the United States absent applicable exemptions. The immediate share price impact was not clear from available public information.



Please wait processing your request...